GlassScriptPhysician profile
Vlassi Baktidy
NPI 1295731800
$8,290.31
in general payments reported to CMS, 2019-2025
34 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $598 · 2021: $1,110 · 2022: $1,213 · 2023: $1,316 · 2024: $1,733 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,570 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,569.66 |
| Education | $265.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,902.04 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,461.91 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $951.13 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $632.98 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $310.06 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $303.65 | 2019-2024 | |
| Genzyme Corporation | $288.85 | 2021-2025 | |
| Harmony Biosciences LLC | $288.77 | 2021-2025 | Wakix |
| Actelion Pharmaceuticals US, INC. | $270.48 | 2024-2025 | Opsumit, Uptravi |
| Philips North America LLC | $244.94 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Baxter Healthcare | $172.39 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $165.23 | 2025 | Ohtuvayre |
| Electromed, INC. | $150.60 | 2021-2025 | Smartvest |
| Viatris Specialty LLC | $147.55 | 2025 | Yupelri |
| United Therapeutics Corporation | $122.79 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93.95 | 2023-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $88.66 | 2020-2023 | Belsomra |
| Genentech USA, INC. | $87.03 | 2019-2022 | |
| Resmed Corp | $80.71 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.03 | 2020-2025 | Glassia |
| Advanced Respiratory, INC | $61.84 | 2020-2021 | |
| Grifols USA, LLC | $50.69 | 2023-2024 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $47.41 | 2021 | |
| Pfizer INC. | $45.74 | 2019-2022 | |
| Axsome Therapeutics, INC. | $40.88 | 2024-2025 | Sunosi |
| Insmed, INC. | $39.76 | 2022-2023 | Arikayce |
| Zoll Respicardia, INC. | $34.45 | 2024 | Remede System |
| Teva Pharmaceuticals USA, INC. | $27.53 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $25.35 | 2022 | |
| Inspire Medical Systems, INC. | $18.08 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $15.12 | 2023 | Quviviq |
| 3b Medical, INC. | $15.01 | 2025 | Luna |
| Ventec Life Systems, INC. | $14.66 | 2020 | |
| Shire North American Group INC | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vlassi Baktidy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.